Cargando…
The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Dyslipidemia, a condition implying high cardiovascular risks, has been widely studied on its potential nutrition interventions, including functional foods. This study aims to examine the effect of nattokinase monascus supplements (NMSs) on cardiovascular biomarkers and carotid intima-media thickness...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574353/ https://www.ncbi.nlm.nih.gov/pubmed/37836525 http://dx.doi.org/10.3390/nu15194239 |
_version_ | 1785120674612772864 |
---|---|
author | Liu, Xiaoming Zeng, Xuejiao Mahe, Jinli Guo, Kai He, Panpan Yang, Qianwen Zhang, Zhiwei Li, Zhongxia Wang, Di Zhang, Zheqing Wang, Lei Jing, Lipeng |
author_facet | Liu, Xiaoming Zeng, Xuejiao Mahe, Jinli Guo, Kai He, Panpan Yang, Qianwen Zhang, Zhiwei Li, Zhongxia Wang, Di Zhang, Zheqing Wang, Lei Jing, Lipeng |
author_sort | Liu, Xiaoming |
collection | PubMed |
description | Dyslipidemia, a condition implying high cardiovascular risks, has been widely studied on its potential nutrition interventions, including functional foods. This study aims to examine the effect of nattokinase monascus supplements (NMSs) on cardiovascular biomarkers and carotid intima-media thickness (CIMT) in patients with dyslipidemia. A total of 113 eligible subjects were randomly assigned to receive either NMSs or a placebo (55 and 58, respectively). After a 120-day intervention, there were significant mean absolute changes in total cholesterol (TC), low-density cholesterol (LDL-C), non-high-density cholesterol (non-HDL-C), and low-density cholesterol to high-density cholesterol ratio (LDL-C to HDL-C ratio), with values of −0.52 (95% CI: −0.51 to −0.54) mmol/L, −0.43 (95% CI: −0.45 to −0.41) mmol/L, −0.52 (95% CI: −0.52 to −0.52) mmol/L, and −0.29 (95% CI: −0.30 to −0.28) mmol/L, respectively, between the two groups. However, no significant differences were found in triglycerides (TGs), high-density cholesterol (HDL-C), and CIMT. Furthermore, the results for lipids and CIMT remained essentially unchanged after adjusting for various confounding factors using the analysis of covariance model. There were no significant differences in coagulation, liver function, renal function, or other indicators. No intervention-related adverse events, such as mouth ulcers, drooling, and stomach pain, were reported. The study results demonstrate that NMSs can ameliorate lipid levels (TC, LDL-C, non-HDL-C, and the LDL-C to HDL-C ratio) without the occurrence of adverse events. However, it did not significantly affect serum TG, HDL-C, and CIMT. |
format | Online Article Text |
id | pubmed-10574353 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105743532023-10-14 The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial Liu, Xiaoming Zeng, Xuejiao Mahe, Jinli Guo, Kai He, Panpan Yang, Qianwen Zhang, Zhiwei Li, Zhongxia Wang, Di Zhang, Zheqing Wang, Lei Jing, Lipeng Nutrients Article Dyslipidemia, a condition implying high cardiovascular risks, has been widely studied on its potential nutrition interventions, including functional foods. This study aims to examine the effect of nattokinase monascus supplements (NMSs) on cardiovascular biomarkers and carotid intima-media thickness (CIMT) in patients with dyslipidemia. A total of 113 eligible subjects were randomly assigned to receive either NMSs or a placebo (55 and 58, respectively). After a 120-day intervention, there were significant mean absolute changes in total cholesterol (TC), low-density cholesterol (LDL-C), non-high-density cholesterol (non-HDL-C), and low-density cholesterol to high-density cholesterol ratio (LDL-C to HDL-C ratio), with values of −0.52 (95% CI: −0.51 to −0.54) mmol/L, −0.43 (95% CI: −0.45 to −0.41) mmol/L, −0.52 (95% CI: −0.52 to −0.52) mmol/L, and −0.29 (95% CI: −0.30 to −0.28) mmol/L, respectively, between the two groups. However, no significant differences were found in triglycerides (TGs), high-density cholesterol (HDL-C), and CIMT. Furthermore, the results for lipids and CIMT remained essentially unchanged after adjusting for various confounding factors using the analysis of covariance model. There were no significant differences in coagulation, liver function, renal function, or other indicators. No intervention-related adverse events, such as mouth ulcers, drooling, and stomach pain, were reported. The study results demonstrate that NMSs can ameliorate lipid levels (TC, LDL-C, non-HDL-C, and the LDL-C to HDL-C ratio) without the occurrence of adverse events. However, it did not significantly affect serum TG, HDL-C, and CIMT. MDPI 2023-09-30 /pmc/articles/PMC10574353/ /pubmed/37836525 http://dx.doi.org/10.3390/nu15194239 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Liu, Xiaoming Zeng, Xuejiao Mahe, Jinli Guo, Kai He, Panpan Yang, Qianwen Zhang, Zhiwei Li, Zhongxia Wang, Di Zhang, Zheqing Wang, Lei Jing, Lipeng The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial |
title | The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial |
title_full | The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial |
title_fullStr | The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial |
title_full_unstemmed | The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial |
title_short | The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial |
title_sort | effect of nattokinase-monascus supplements on dyslipidemia: a four-month randomized, double-blind, placebo-controlled clinical trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574353/ https://www.ncbi.nlm.nih.gov/pubmed/37836525 http://dx.doi.org/10.3390/nu15194239 |
work_keys_str_mv | AT liuxiaoming theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT zengxuejiao theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT mahejinli theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT guokai theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT hepanpan theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT yangqianwen theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT zhangzhiwei theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT lizhongxia theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT wangdi theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT zhangzheqing theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT wanglei theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT jinglipeng theeffectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT liuxiaoming effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT zengxuejiao effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT mahejinli effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT guokai effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT hepanpan effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT yangqianwen effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT zhangzhiwei effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT lizhongxia effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT wangdi effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT zhangzheqing effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT wanglei effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial AT jinglipeng effectofnattokinasemonascussupplementsondyslipidemiaafourmonthrandomizeddoubleblindplacebocontrolledclinicaltrial |